Oraverse Injection, Solution
Product Images NDC 0362-0101

4 FDA label images from Septodont, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Oraverse (NDC 0362-0101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Septodont, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ndc 0362 0101 10

Ndc 0362 0101 10
Packaging label for Oraverse (Phentolamine Mesylate) Injection, 0.4 mg/1.7 mL, a submucosal injection solution. The label shows the product name, generic name with strength, and an illustration of a cartridge with an arrow. It indicates contents of 10 cartridges per package, distributed by Septodont, Inc., and made in Canada by Novocol Pharmaceutical of Canada, Inc.*
FDA Label Image

Chemical Structure (Oraverse 01)

Chemical Structure (Oraverse 01)
Chemical structure diagram of Phentolamine Mesylate, the active ingredient in Oraverse injection solution. The structure shows the arrangement of atoms and bonds characteristic of the molecule.*
FDA Label Image

Figure 1 (Oraverse 02)

Figure 1 (Oraverse 02)
A Kaplan-Meier curve comparing the proportion of patients with normal sensation over time between OraVerse and Control groups. The x-axis represents time in minutes up to 300, and the y-axis shows the proportion of patients with normal sensation from 0 to 100%. The OraVerse group (black line) reaches higher proportions faster than the Control group (gray line). Censored data points are marked with small squares.*
FDA Label Image

Figure 2 (Oraverse 03)

Figure 2 (Oraverse 03)
A Kaplan-Meier curve comparing the proportion of patients with normal sensation over time (minutes) between OraVerse and a control group. The chart shows faster recovery with OraVerse compared to control, with median recovery times listed for each group. Censored data points are marked.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.